PROCEPT BioRobotics Posts Remarkable Q3 Financial Performance
PROCEPT BioRobotics Corporation (NASDAQ: PRCT), recognized for its innovative surgical robotics, recently shared its impressive financial results for the quarter that ended September 30, 2024. This report highlights a significant leap in revenue and an optimistic outlook for the rest of the year.
Record Revenue Growth
Impressive Third Quarter Numbers
During the third quarter of 2024, a total revenue of $58.4 million was recorded, reflecting an incredible 66% increase compared to the same period in 2023. Such growth underscores the success in both sales and operational efficiency.
U.S. Market Performance
Within the U.S. market, handpiece and consumables revenue reached an astounding $29.6 million, marking a 74% increase year-over-year. The company sold 45 robotic systems in the U.S. with an average selling price hovering around $432,000, adding to the robust performance.
International Revenue Surge
Global Expansion
International revenue also saw remarkable growth, totaling $6.2 million, which represents a staggering 122% increase from the previous year. This expansion illustrates PROCEPT's growing global footprint and acceptance of its products.
Gross Margins and Financial Health
The company reported a record gross margin of 63.2% in the third quarter, up from 53.8% in the previous year. This improvement is attributed to better overhead absorption and increased sales prices of robotic systems in the U.S.
Future Guidance and Expectations
Increased Revenue Guidance
Looking ahead, PROCEPT BioRobotics has adjusted its fiscal year 2024 revenue guidance, now projecting total revenue between $222.5 million and $223.0 million, an upward revision from previous forecasts. This anticipated growth reflects a year-over-year increase of 63% to 64%.
Adjusted EBITDA Transformation
Additionally, the company raised its guidance for adjusted EBITDA, now estimating a loss of $60 million for the full year. Although still a loss, this figure has improved from previous projections.
Operational Insights
Development and Marketing Expenses
For the third quarter, operating expenses were reported at $59.3 million, an increase driven primarily by marketing and research costs aimed at scaling its operations and enhancing product offerings.
Net Loss vs Prior Year
The company reported a net loss of $21 million for Q3 2024, down from a loss of $24.6 million in the same quarter the previous year. Additionally, adjusted EBITDA loss improved from $19.4 million in 2023 to $12.4 million in the recent quarter.
Cash Flow and Reserves
Strong Liquidity Position
As of September 30, 2024, PROCEPT holds $199.8 million in cash and equivalents, allowing for significant flexibility as it continues to invest in growth and product development.
Conclusion
PROCEPT BioRobotics stands at a strong position with its recent financial results showcasing robust growth across various segments. With an enhanced outlook for 2024 and substantial cash reserves, the company is well-poised to further expand its market presence and innovate within the surgical robotics arena.
Frequently Asked Questions
What were PROCEPT BioRobotics' total revenues in Q3 2024?
The company reported total revenues of $58.4 million, marking a 66% increase year-over-year.
How much did the company's international revenue grow in Q3 2024?
International revenue increased by 122% to $6.2 million compared to the same period last year.
What is the current adjusted EBITDA guidance for PROCEPT?
The adjusted EBITDA guidance for the full year 2024 has been set at a loss of $60 million.
What were the operating expenses for Q3 2024?
Operating expenses were $59.3 million, an increase driven largely by marketing and R&D costs.
How much cash does PROCEPT BioRobotics currently hold?
As of September 30, 2024, the company reported cash and cash equivalents of $199.8 million.
